LifeSci Capital analyst Sam Slutsky maintained a Buy rating on OnKure Therapeutics today and set a price target of $21.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sam Slutsky has given his Buy rating due to a combination of factors including OnKure Therapeutics’ promising clinical developments and strategic advancements. The company is set to present data from its Phase 1 PIKture-01 trial for their PI3Kα inhibitor, OKI-219, in ER+ breast cancer by Q1 2026, which is expected to include mature datasets from monotherapy and combination arms. This data will provide insights into the drug’s combinability and potential efficacy, which are crucial for its future positioning in the competitive landscape of advanced ER+ breast cancer treatments.
Additionally, OnKure is making strides in selecting a pan-PI3Kα mutant selective molecule, with plans to reveal further details in early 2026. The company is also exploring expansion into vascular malformations, indicating a strategic diversification into areas with unmet medical needs. Financially, OnKure ended Q3 2025 with a solid cash position of $70.3 million, which should support their operations for over a year, reflecting a stable financial outlook that supports ongoing and future research initiatives.
In another report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $30.00 price target.